Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:GU5's EV-to-OCF is ranked worse than 68.6% of 121
companies
in the Medical Distribution industry
Industry Median: 7.98
vs FRA:GU5: 13.68
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's PE Ratio (TTM) for today is calculated as:
Guangzhou Baiyunshan Pharmaceutical Holdings Co's share price for today is €1.45.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.197.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-OCF Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-OCF Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-OCF vs Medical Distribution Industry
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Enterprise Value is €5,070 Mil.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €353 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a EV-to-OCF of 14.38 as of Sep. 06, 2026. This is 12% above median its historical median of 12.88. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #83 out of 121 companies in the Medical Distribution industry, placing it in the top 68.6%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-OCF too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-OCF of 14.38 is 12% above median its 10-year median of 12.88. The Medical Distribution industry median EV-to-OCF is 7.98. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 14.38 is 80.2% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #83 out of 121 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-OCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #83 out of 121 companies for EV-to-OCF. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. The industry median EV-to-OCF is 7.98. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 14.38 is 80.2% above this benchmark. While the company's 10-year median is 12.88 vs. the industry median of 7.98, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Distribution company?
The median EV-to-OCF among Medical Distribution companies is 7.98, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-OCF of 14.38 is 80.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median EV-to-OCF is 7.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-OCF is 14.38, which is 12% above median its own 10-year median of 12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.22, compared to a current price of €1.45 — trading 34.7% below its estimated fair value. The current EV-to-OCF is 14.38, which is 12% above median its 10-year median of 12.88 and 80.2% above the Medical Distribution industry median of 7.98. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current EV-to-OCF is 14.38 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.45 is trading 34.7% below its estimated GF Value™ of €2.22.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
EV-to-OCF: 14.38 (12% above median its 10-year median of 12.88)
GF Value™: €2.22 vs. price of €1.45 (34.7% below fair value)
Industry Position: 80.2% above the Medical Distribution median (#83 of 121)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
70GF Score
Get the complete analysis for FRA:GU5
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
